TY - JOUR
T1 - Effect of camostat mesilate for the treatment of advanced diabetic nephropathy
AU - Matsubara, Mitsunobu
AU - Taguma, Yoshio
AU - Kurosawa, Kosei
AU - Hotta, Osamu
AU - Suzuki, Kazuyuki
AU - Ishizaki, Makoto
PY - 1990/8
Y1 - 1990/8
N2 - Carnostat mesilate is a developed derivative of gabexate mesllate for oral administration and is known to be one of the most potent protease inhibitors. We administered this drug to 15 patients with advanced diabetic nephropothy at a daily dose of 600 mg for 4 to 6 weeks. All patients had been treated with conventional therapy including angtotensin-converting enzyme inhibitors, and their diseases had stabilized for at least 2 weeks before the camostat mesilate therapy. Urinary protein excretion decreased promptly from 4.8 ± 0.6 to 2.9 ± 0.4 gm/day (mean ± SEM, p < 0.01) and serum albumin level increased from 2.7 ± 0.2 gm/dl to 2.9 ± 0.2 gm/dl (mean ± SEM, p < 0.05) within 4 to 6 weeks. The amount of plasma fibrinogen significantly decreased from 419.7 ± 42.3 mg/dl to 306.6 ± 28.3 mg/dl (mean ± SEM, p < 0.01), and urinary total fibrinogen degradation product excretion over 24 hours also decreased from 26,118 ± 9,696 to 18,072 ± 7,107 μg/day (mean ± SEM, P < 0.05). The value for serum creatinine level did not change during this intervention. We suggest that camostat mesilate suppresses the hypercoagulable state originating from diabetes meilltus, and changes the permselectivity of the glomerular capillary wall. These effects of camostat mesilate may improve the prognosis of diabetic nephropathy.
AB - Carnostat mesilate is a developed derivative of gabexate mesllate for oral administration and is known to be one of the most potent protease inhibitors. We administered this drug to 15 patients with advanced diabetic nephropothy at a daily dose of 600 mg for 4 to 6 weeks. All patients had been treated with conventional therapy including angtotensin-converting enzyme inhibitors, and their diseases had stabilized for at least 2 weeks before the camostat mesilate therapy. Urinary protein excretion decreased promptly from 4.8 ± 0.6 to 2.9 ± 0.4 gm/day (mean ± SEM, p < 0.01) and serum albumin level increased from 2.7 ± 0.2 gm/dl to 2.9 ± 0.2 gm/dl (mean ± SEM, p < 0.05) within 4 to 6 weeks. The amount of plasma fibrinogen significantly decreased from 419.7 ± 42.3 mg/dl to 306.6 ± 28.3 mg/dl (mean ± SEM, p < 0.01), and urinary total fibrinogen degradation product excretion over 24 hours also decreased from 26,118 ± 9,696 to 18,072 ± 7,107 μg/day (mean ± SEM, P < 0.05). The value for serum creatinine level did not change during this intervention. We suggest that camostat mesilate suppresses the hypercoagulable state originating from diabetes meilltus, and changes the permselectivity of the glomerular capillary wall. These effects of camostat mesilate may improve the prognosis of diabetic nephropathy.
UR - http://www.scopus.com/inward/record.url?scp=0025160281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025160281&partnerID=8YFLogxK
M3 - Article
C2 - 2394938
AN - SCOPUS:0025160281
VL - 116
SP - 206
EP - 210
JO - Translational Research
JF - Translational Research
SN - 1931-5244
IS - 2
ER -